

IN THE CLAIMS

Claims 1-80 (canceled)

Claim 81 (new): A homogenous preparation of recombinant soluble FcγRIIb or FcγRIII, the receptor being characterized by the absence of a transmembrane domain, signal peptide and glycosylation, the said preparation being obtainable by expression of a nucleic acid encoding such receptor in prokaryotes under conditions that lead to production of insoluble inclusion bodies and renaturation of the receptor molecules from the inclusion bodies.

Claim 82 (new): The homogenous preparation of claim 81, wherein the receptor contains one of the amino acid sequences as shown in SEQ ID NOs. 3 and 4.

Claim 83 (new): The homogenous preparation of claim 81, wherein the receptor is of human origin.

Claim 84 (new): Pharmaceutical composition, containing a homogenous preparation of a recombinant soluble FcγRIIb or FcγRIII receptor according to claim 81.

Claim 85 (new): Pharmaceutical composition according to claim 84 for use in the treatment or prevention of autoimmune diseases, allergies or tumor diseases.

Claim 86 (new): Pharmaceutical composition according to claim 84 for use in the treatment of AIDS, rheumatoid arthritis or multiple myeloma.

Claim 87 (new) The recombinant nucleic acid containing a sequence encoding a recombinant Fc receptor according to claim 81, wherein said nucleic acid is contained on a prokaryotic expression vector.

Claim 88 (new): The recombinant nucleic acid according to claim 87, wherein said nucleic acid contains one of the sequences shown in one of SEQ ID Nos: 7-12

Claim 89 (new): The recombinant nucleic acid according to claim 87, wherein said nucleic acid additionally contains expression control sequences operably linked to the sequence encoding the recombinant Fc receptor.

Claim 90 (new): A host cell characterized by the presence of a recombinant nucleic acid according to claim 87, wherein said cell is a prokaryotic host cell.

Claim 91 (new) The homogenous preparation of claim 82, wherein the receptor is of human origin.

Claim 92 (new): Pharmaceutical composition, containing a homogenous preparation of a recombinant soluble FcγRIIb or FcγRIII receptor according to claim 82.

Claim 93 (new) Pharmaceutical composition, containing a homogenous preparation of a recombinant soluble FcγRIIb or FcγRIII receptor according to claim 83.

Claim 94 (new): Pharmaceutical composition according to claim 85 for use in the treatment of AIDS, rheumatoid arthritis or multiple myeloma.